[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Editor's Correspondence
July 23, 2012

A Different Perspective Regarding Prostate-Specific Antigen Testing

Author Affiliations

Author Affiliation: Department of Internal Medicine, Texas Tech Health Sciences Center, El Paso.

Arch Intern Med. 2012;172(14):1110-1114. doi:10.1001/archinternmed.2012.2038

I wish to provide a different perspective regarding prostate-specific antigen (PSA) testing and prostate cancer to the one reported by Dr Bennet.1 I was diagnosed as having prostate cancer at a similar age to Dr Bennet (57 years) some 6 years ago. I had routinely checked my PSA on a yearly basis, and it was typically around 2.0 ng/mL (to convert to micrograms per liter, multiply by 1). When retested it went up to 3.3 ng/mL, an unusual increase compared with my previous values but still within what was considered the “normal range.” Despite that, I was concerned about the sudden increase. I had symptoms of benign prostatic hyperplasia, and my father had prostate cancer in his mid 70s. I decided to consult a urologist colleague. On examination, my prostate was slightly asymmetric but without nodules. My urologist told me it was very unlikely to have prostate cancer but recommended a biopsy because of my family history. One of 10 biopsy specimens was reported positive for prostate cancer, with a Gleason score of 6 (3 + 3).